The Federal Trade Commission and a coalition of states have secured a $49.75 million settlement with Progress Residential, LLC and its owner, Pretium Partners, resolving allegations that the companies used deceptive rental pricing and engaged in related unlawful conduct in the single-family rental market. The action is notable not only for its size, but also for where regulators aimed it: fee and pricing practices in a fast-growing segment of institutional housing.

According to the FTC, the case focused on allegedly misleading representations about the true cost of renting homes, along with other practices affecting tenants during the leasing process and tenancy.

A New Mexico state judge has ordered Meta to pay $25 billion after a jury found the company liable for deceiving Facebook users about privacy practices in litigation tied to the Cambridge Analytica fallout. The ruling, issued by Judge Francis J. Mathew in New Mexico state district court, is notable not just because of the underlying allegations, but because of the sheer size of the award—placing it among the most significant privacy-related judgments ever entered against a technology company.

The case centers on claims that Facebook users were misled about how their personal data would be accessed, shared, and exploited, issues that became globally prominent after revelations involving Cambridge Analytica.

The FTC’s October 2026 consumer-protection docket may not feature a marquee headline case, but it does send a clear signal: pricing practices remain an active enforcement priority. This month’s announcements include a settlement with an auto dealership group over alleged price-transparency issues and enforcement activity involving major wholesale T-shirt distributors over fair-pricing concerns.

For businesses, the takeaway is straightforward.

The Federal Trade Commission has filed suit against REPS Company, alleging the ticket broker used unlawful and deceptive methods to evade ticket-purchase limits and acquire millions of tickets for high-demand live events. The case, brought as U.S. v. REPS Company, Inc., puts a spotlight on practices that have long drawn scrutiny in the live-entertainment market: bulk purchasing, circumvention of platform controls, and the use of technological workarounds to outmaneuver ordinary consumers.

According to the FTC, REPS allegedly manipulated online ticketing systems designed to enforce purchase caps and preserve fair access.

The Federal Trade Commission has announced a settlement with an auto dealership group over alleged price-transparency issues, underscoring that dealer advertising, pricing disclosures, and add-on fee practices remain a live enforcement priority. Even without a headline-grabbing court opinion attached, the matter is important: it shows the agency continuing to police how vehicle prices and fees are presented to consumers, particularly where advertised prices may not clearly reflect the actual amount a buyer is expected to pay.

For auto retailers and their counsel, the takeaway is straightforward.

The Federal Trade Commission announced a settlement with an auto dealership group that it framed as a win for price transparency, underscoring how aggressively the agency continues to police vehicle advertising and sales practices. Even without a fully detailed complaint publicly highlighted in the initial announcement, the action is notable as a same-day federal consumer-protection development with immediate relevance for dealerships, their counsel, and compliance teams.

At a high level, the settlement appears aimed at one of the FTC’s core concerns in the auto-retail space: whether advertised or quoted prices accurately reflect what consumers will actually pay.

The Federal Trade Commission has issued warning letters to 24 of the nation’s largest healthcare services companies, putting major hospital and health-system operators on notice that patient pricing practices remain a live consumer-protection priority. Although the agency has not filed an enforcement action, the letters are legally significant: they serve as a public signal that the FTC is scrutinizing whether providers’ pricing disclosures, estimates, and patient-facing cost information could mislead consumers.

The message from FTC leadership is straightforward.

The Federal Trade Commission, joined by the attorneys general of Utah and Nevada, has filed a new consumer-protection action against Lens.com, alleging the online contact-lens seller misrepresented prices in search advertisements and on its website over an extended period. According to regulators, the company used pricing tactics that made products appear cheaper than they actually were, a theory that puts digital advertising, checkout design, and price disclosures squarely at issue.

The case is notable not only because of the parties involved, but because it reflects continued FTC focus on “drip pricing” and other online marketing practices that can distort a consumer’s understanding of total cost.

Florida Attorney General James Uthmeier has filed a state-court action against Pfizer and its CEO, Albert Bourla, alleging the company misled consumers about the safety and effectiveness of Pfizer’s COVID-19 vaccine. The suit adds a high-profile state enforcement action to the already complex body of litigation stemming from pandemic-era vaccine marketing, and it could become a closely watched test of how far state consumer-protection laws can reach in disputes over pharmaceutical communications.

At its core, the case appears to frame vaccine-related statements not simply as scientific or regulatory matters, but as actionable representations to consumers.

A New Mexico jury has delivered a striking win for state tech enforcement, finding that Meta willfully lied on 26 separate occasions in a case centered on data privacy, hate speech, misinformation, and the company’s post-Cambridge Analytica investigation of third-party app developers. The verdict stands out not just for its breadth, but for the jury’s apparent willingness to treat alleged misstatements across multiple content and privacy issues as part of a larger pattern of deceptive conduct.

For legal observers, the significance goes beyond the headlines.

The Federal Trade Commission has sued Humboldt Merchant Services, alleging the payment processor knowingly enabled scam operators and shell merchants to access the payments system for unauthorized billing and deceptive consumer charges. The agency’s theory is notable: rather than focusing only on the merchants that allegedly carried out the scams, the FTC is aiming at the infrastructure provider it says made those schemes possible.

According to the FTC, Humboldt processed payments for entities tied to sham businesses and billing operations that allegedly lacked legitimate merchant activity.

A new proposed consumer class action in the District of Nevada puts Vitauthority LLC’s supplement marketing under scrutiny. In Mathieson v. Vitauthority LLC, No. 2:26-cv-02828, the plaintiff challenges how the company allegedly marketed and sold certain products, teeing up the kind of labeling and advertising dispute that continues to drive class action filings in the health-and-wellness space.

Although the complaint details will matter, the putative class appears to center on consumers who purchased Vitauthority products and allegedly paid a premium based on the company’s representations.

The Federal Trade Commission has rescinded a Biden-era policy statement that had expanded expectations around breach notifications for certain health apps and connected-device providers. The move is part of a broader agency push toward regulatory streamlining, but it also sends a clear signal to the digital-health market: the FTC may be narrowing how aggressively it interprets and enforces health-data breach obligations outside traditional healthcare settings.

At issue is the FTC’s approach to the Health Breach Notification Rule, which applies to certain vendors of personal health records and related entities not covered by HIPAA.

The Federal Trade Commission and the State of Connecticut have announced a $4 million settlement with Manchester City Nissan over alleged deceptive-fee practices, marking another notable enforcement action aimed at dealer pricing transparency. The matter is particularly significant because it underscores continued coordination between federal and state regulators in policing so-called “junk fees” and other allegedly misleading charges in consumer transactions.

According to the FTC, the case focused on allegations that the dealership used deceptive fees in connection with vehicle sales.

Federal regulators have taken a consequential step in the fast-evolving kratom market by moving to schedule three highly potent kratom-related derivatives that authorities say act like opioids. The action marks a notable escalation beyond longstanding debates over kratom itself, focusing instead on newer, concentrated compounds that have become increasingly common in smoke shops, vape stores, and convenience outlets.

For the industry, the immediate significance is practical as much as political: once a substance is scheduled, the legal landscape changes quickly.